ID   ADCY6_RAT               Reviewed;        1166 AA.
AC   Q03343;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1993, sequence version 1.
DT   02-OCT-2024, entry version 183.
DE   RecName: Full=Adenylate cyclase type 6;
DE            EC=4.6.1.1 {ECO:0000269|PubMed:1409703, ECO:0000269|PubMed:15385642, ECO:0000269|PubMed:17110384, ECO:0000269|PubMed:21606183, ECO:0000269|PubMed:9391159};
DE   AltName: Full=ATP pyrophosphate-lyase 6;
DE   AltName: Full=Adenylate cyclase type VI;
DE            Short=ACVI;
DE   AltName: Full=Adenylyl cyclase 6;
DE            Short=AC6 {ECO:0000303|PubMed:9391159};
DE   AltName: Full=Ca(2+)-inhibitable adenylyl cyclase;
GN   Name=Adcy6;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1332969; DOI=10.1016/s0021-9258(18)35842-3;
RA   Krupinski J., Lehman T.C., Frankenfield C.D., Zwaagstra J.C., Watson P.A.;
RT   "Molecular diversity in the adenylylcyclase family. Evidence for eight
RT   forms of the enzyme and cloning of type VI.";
RL   J. Biol. Chem. 267:24858-24862(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, ACTIVITY
RP   REGULATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=1409703; DOI=10.1073/pnas.89.20.9809;
RA   Premont R.T., Chen J., Ma H.-W., Ponnapalli M., Iyengar R.;
RT   "Two members of a widely expressed subfamily of hormone-stimulated adenylyl
RT   cyclases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:9809-9813(1992).
RN   [3]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, SUBCELLULAR LOCATION, ACTIVITY
RP   REGULATION, MUTAGENESIS OF SER-660, AND PHOSPHORYLATION AT SER-660.
RX   PubMed=9391159; DOI=10.1073/pnas.94.25.14100;
RA   Chen Y., Harry A., Li J., Smit M.J., Bai X., Magnusson R., Pieroni J.P.,
RA   Weng G., Iyengar R.;
RT   "Adenylyl cyclase 6 is selectively regulated by protein kinase A
RT   phosphorylation in a region involved in Galphas stimulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:14100-14104(1997).
RN   [4]
RP   PHOSPHORYLATION AT SER-554; SER-660 AND THR-917, AND MUTAGENESIS OF
RP   SER-311; SER-554; SER-660 AND THR-917.
RX   PubMed=11877398; DOI=10.1074/jbc.m111537200;
RA   Lin T.-H., Lai H.-L., Kao Y.-Y., Sun C.-N., Hwang M.-J., Chern Y.;
RT   "Protein kinase C inhibits type VI adenylyl cyclase by phosphorylating the
RT   regulatory N domain and two catalytic C1 and C2 domains.";
RL   J. Biol. Chem. 277:15721-15728(2002).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, PHOSPHORYLATION BY RAF1,
RP   INTERACTION WITH RAF1, AND ACTIVITY REGULATION.
RX   PubMed=15385642; DOI=10.1124/mol.66.4.921;
RA   Ding Q., Gros R., Gray I.D., Taussig R., Ferguson S.S., Feldman R.D.;
RT   "Raf kinase activation of adenylyl cyclases: isoform-selective
RT   regulation.";
RL   Mol. Pharmacol. 66:921-928(2004).
RN   [6]
RP   CATALYTIC ACTIVITY, FUNCTION, ACTIVITY REGULATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=17110384; DOI=10.1074/jbc.m607522200;
RA   Gao X., Sadana R., Dessauer C.W., Patel T.B.;
RT   "Conditional stimulation of type V and VI adenylyl cyclases by G protein
RT   betagamma subunits.";
RL   J. Biol. Chem. 282:294-302(2007).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND TISSUE SPECIFICITY.
RX   PubMed=21606183; DOI=10.1093/cvr/cvr137;
RA   Nelson C.P., Rainbow R.D., Brignell J.L., Perry M.D., Willets J.M.,
RA   Davies N.W., Standen N.B., Challiss R.A.;
RT   "Principal role of adenylyl cyclase 6 in K? channel regulation and
RT   vasodilator signalling in vascular smooth muscle cells.";
RL   Cardiovasc. Res. 91:694-702(2011).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-53 AND SER-574, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Catalyzes the formation of the signaling molecule cAMP
CC       downstream of G protein-coupled receptors (PubMed:1409703,
CC       PubMed:15385642, PubMed:17110384, PubMed:21606183). Functions in
CC       signaling cascades downstream of beta-adrenergic receptors in the heart
CC       and in vascular smooth muscle cells (PubMed:21606183). Functions in
CC       signaling cascades downstream of the vasopressin receptor in the kidney
CC       and has a role in renal water reabsorption. Functions in signaling
CC       cascades downstream of PTH1R and plays a role in regulating renal
CC       phosphate excretion. Functions in signaling cascades downstream of the
CC       VIP and SCT receptors in pancreas and contributes to the regulation of
CC       pancreatic amylase and fluid secretion (By similarity). Signaling
CC       mediates cAMP-dependent activation of protein kinase PKA
CC       (PubMed:21606183). This promotes increased phosphorylation of various
CC       proteins, including AKT. Plays a role in regulating cardiac
CC       sarcoplasmic reticulum Ca(2+) uptake and storage, and is required for
CC       normal heart ventricular contractibility. May contribute to normal
CC       heart function (By similarity). Mediates vasodilatation after
CC       activation of beta-adrenergic receptors by isoproterenol (By
CC       similarity). Contributes to bone cell responses to mechanical stimuli
CC       (By similarity). {ECO:0000250|UniProtKB:O43306,
CC       ECO:0000250|UniProtKB:Q01341, ECO:0000269|PubMed:1409703,
CC       ECO:0000269|PubMed:15385642, ECO:0000269|PubMed:17110384,
CC       ECO:0000269|PubMed:21606183}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP = 3',5'-cyclic AMP + diphosphate; Xref=Rhea:RHEA:15389,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:33019, ChEBI:CHEBI:58165; EC=4.6.1.1;
CC         Evidence={ECO:0000269|PubMed:1409703, ECO:0000269|PubMed:15385642,
CC         ECO:0000269|PubMed:17110384, ECO:0000269|PubMed:21606183,
CC         ECO:0000269|PubMed:9391159};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:15385642};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:15385642, ECO:0000269|PubMed:9391159};
CC       Note=Binds 2 magnesium ions per subunit. Is also active with manganese
CC       (in vitro). {ECO:0000250|UniProtKB:P30803};
CC   -!- ACTIVITY REGULATION: Activated by G(s) G alpha protein GNAS
CC       (PubMed:17110384, PubMed:9391159). Inhibited by G(i) G alpha protein
CC       GNAI1 (By similarity). Is further activated by the complex formed by
CC       GNB1 and GNG2 (PubMed:17110384). Activated by forskolin (By
CC       similarity). Inhibited by calcium ions, already at micromolar
CC       concentrations (By similarity). Inhibited by adenosine, AMP and their
CC       analogs (By similarity). Phosphorylation by RAF1 results in its
CC       activation (PubMed:15385642). {ECO:0000250|UniProtKB:P30804,
CC       ECO:0000250|UniProtKB:Q01341, ECO:0000269|PubMed:15385642,
CC       ECO:0000269|PubMed:17110384, ECO:0000269|PubMed:9391159}.
CC   -!- SUBUNIT: Part of a complex containing AKAP5, ADCY5, PDE4C and PKD2 (By
CC       similarity). Interacts with RAF1 (PubMed:15385642). Interacts (via
CC       cytoplasmic N-terminus) with GNAS, GNB1 and GNG2 (By similarity).
CC       {ECO:0000250|UniProtKB:O43306, ECO:0000250|UniProtKB:Q01341,
CC       ECO:0000269|PubMed:15385642}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15385642,
CC       ECO:0000269|PubMed:17110384, ECO:0000269|PubMed:9391159}; Multi-pass
CC       membrane protein {ECO:0000305}. Cell projection, cilium
CC       {ECO:0000250|UniProtKB:Q01341}. Cell projection, stereocilium
CC       {ECO:0000250|UniProtKB:Q01341}.
CC   -!- TISSUE SPECIFICITY: Detected in brain and kidney (PubMed:1409703).
CC       Detected in vascular smooth muscle cells (PubMed:21606183).
CC       {ECO:0000269|PubMed:1409703, ECO:0000269|PubMed:21606183}.
CC   -!- DOMAIN: The protein contains two modules with six transmembrane helices
CC       each; both are required for catalytic activity. Isolated N-terminal or
CC       C-terminal guanylate cyclase domains have no catalytic activity, but
CC       when they are brought together, enzyme activity is restored. The active
CC       site is at the interface of the two domains. Both contribute substrate-
CC       binding residues, but the catalytic metal ions are bound exclusively
CC       via the N-terminal guanylate cyclase domain.
CC       {ECO:0000250|UniProtKB:P26769}.
CC   -!- PTM: Phosphorylation by RAF1 increases enzyme activity
CC       (PubMed:15385642). Phosphorylation by PKA on Ser-660 inhibits the GNAS-
CC       mediated increase in catalytic activity (PubMed:9391159).
CC       Phosphorylation by PKC on Ser-554, Ser-660 and Thr-917 inhibits
CC       catalytic activity (PubMed:11877398). {ECO:0000269|PubMed:11877398,
CC       ECO:0000269|PubMed:15385642, ECO:0000269|PubMed:9391159}.
CC   -!- SIMILARITY: Belongs to the adenylyl cyclase class-4/guanylyl cyclase
CC       family. {ECO:0000255|PROSITE-ProRule:PRU00099}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA40678.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L01115; AAA40676.1; -; mRNA.
DR   EMBL; M96160; AAA40678.1; ALT_INIT; mRNA.
DR   PIR; A47202; A47202.
DR   RefSeq; NP_036953.4; NM_012821.4.
DR   AlphaFoldDB; Q03343; -.
DR   SMR; Q03343; -.
DR   IntAct; Q03343; 2.
DR   STRING; 10116.ENSRNOP00000072881; -.
DR   BindingDB; Q03343; -.
DR   ChEMBL; CHEMBL2095179; -.
DR   DrugCentral; Q03343; -.
DR   GlyCosmos; Q03343; 2 sites, No reported glycans.
DR   GlyGen; Q03343; 2 sites.
DR   iPTMnet; Q03343; -.
DR   PhosphoSitePlus; Q03343; -.
DR   SwissPalm; Q03343; -.
DR   PaxDb; 10116-ENSRNOP00000016624; -.
DR   GeneID; 25289; -.
DR   KEGG; rno:25289; -.
DR   UCSC; RGD:2035; rat.
DR   AGR; RGD:2035; -.
DR   CTD; 112; -.
DR   RGD; 2035; Adcy6.
DR   eggNOG; KOG3619; Eukaryota.
DR   InParanoid; Q03343; -.
DR   OrthoDB; 3686360at2759; -.
DR   PhylomeDB; Q03343; -.
DR   Reactome; R-RNO-163615; PKA activation.
DR   Reactome; R-RNO-170660; Adenylate cyclase activating pathway.
DR   Reactome; R-RNO-170670; Adenylate cyclase inhibitory pathway.
DR   Reactome; R-RNO-400042; Adrenaline,noradrenaline inhibits insulin secretion.
DR   Reactome; R-RNO-418597; G alpha (z) signalling events.
DR   Reactome; R-RNO-5610787; Hedgehog 'off' state.
DR   PRO; PR:Q03343; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005929; C:cilium; IEA:UniProtKB-SubCell.
DR   GO; GO:0005768; C:endosome; IDA:RGD.
DR   GO; GO:0016020; C:membrane; IDA:BHF-UCL.
DR   GO; GO:0031528; C:microvillus membrane; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0042383; C:sarcolemma; IDA:RGD.
DR   GO; GO:0032420; C:stereocilium; IEA:UniProtKB-SubCell.
DR   GO; GO:0004016; F:adenylate cyclase activity; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008294; F:calcium- and calmodulin-responsive adenylate cyclase activity; IDA:RGD.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0005080; F:protein kinase C binding; ISO:RGD.
DR   GO; GO:0097110; F:scaffold protein binding; ISO:RGD.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:RGD.
DR   GO; GO:0000149; F:SNARE binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0097746; P:blood vessel diameter maintenance; ISO:RGD.
DR   GO; GO:0006171; P:cAMP biosynthetic process; IDA:RGD.
DR   GO; GO:0071870; P:cellular response to catecholamine stimulus; ISO:RGD.
DR   GO; GO:1904322; P:cellular response to forskolin; ISS:UniProtKB.
DR   GO; GO:0071380; P:cellular response to prostaglandin E stimulus; ISO:RGD.
DR   GO; GO:1904117; P:cellular response to vasopressin; ISS:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; IEP:RGD.
DR   GO; GO:0007212; P:G protein-coupled dopamine receptor signaling pathway; ISO:RGD.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   GO; GO:0072660; P:maintenance of protein location in plasma membrane; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0035811; P:negative regulation of urine volume; ISS:UniProtKB.
DR   GO; GO:0003091; P:renal water homeostasis; ISS:UniProtKB.
DR   CDD; cd07302; CHD; 1.
DR   CDD; cd07556; Nucleotidyl_cyc_III; 1.
DR   Gene3D; 3.30.70.1230; Nucleotide cyclase; 2.
DR   InterPro; IPR001054; A/G_cyclase.
DR   InterPro; IPR018297; A/G_cyclase_CS.
DR   InterPro; IPR032628; AC_N.
DR   InterPro; IPR030672; Adcy.
DR   InterPro; IPR009398; Adcy_conserved_dom.
DR   InterPro; IPR029787; Nucleotide_cyclase.
DR   PANTHER; PTHR45627; ADENYLATE CYCLASE TYPE 1; 1.
DR   PANTHER; PTHR45627:SF11; ADENYLATE CYCLASE TYPE 6; 1.
DR   Pfam; PF16214; AC_N; 1.
DR   Pfam; PF06327; Adcy_cons_dom; 1.
DR   Pfam; PF00211; Guanylate_cyc; 2.
DR   PIRSF; PIRSF039050; Ade_cyc; 1.
DR   SMART; SM00044; CYCc; 2.
DR   SUPFAM; SSF55073; Nucleotide cyclase; 2.
DR   PROSITE; PS00452; GUANYLATE_CYCLASE_1; 2.
DR   PROSITE; PS50125; GUANYLATE_CYCLASE_2; 2.
PE   1: Evidence at protein level;
KW   ATP-binding; cAMP biosynthesis; Cell membrane; Cell projection; Cilium;
KW   Glycoprotein; Lyase; Magnesium; Manganese; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome; Repeat;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..1166
FT                   /note="Adenylate cyclase type 6"
FT                   /id="PRO_0000195701"
FT   TOPO_DOM        1..149
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        150..166
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        179..195
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        212..228
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        237..253
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        257..273
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        287..303
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        304..671
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        672..689
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        700..716
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        741..757
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        758..817
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        818..834
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        837..853
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        895..911
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        912..1166
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   BINDING         382..387
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P30803"
FT   BINDING         382
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00099"
FT   BINDING         382
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00099"
FT   BINDING         383
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00099"
FT   BINDING         424..426
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P30803"
FT   BINDING         426
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00099"
FT   BINDING         426
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00099"
FT   BINDING         470
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P30803"
FT   BINDING         1029
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P26769"
FT   BINDING         1103..1105
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P26769"
FT   BINDING         1110..1114
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P26769"
FT   BINDING         1150
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P26769"
FT   MOD_RES         53
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         554
FT                   /note="Phosphoserine; by PKC; in vitro"
FT                   /evidence="ECO:0000269|PubMed:11877398"
FT   MOD_RES         574
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         660
FT                   /note="Phosphoserine; by PKA; in vitro"
FT                   /evidence="ECO:0000269|PubMed:9391159"
FT   MOD_RES         660
FT                   /note="Phosphoserine; by PKC; in vitro"
FT                   /evidence="ECO:0000269|PubMed:11877398"
FT   MOD_RES         917
FT                   /note="Phosphothreonine; by PKC; in vitro"
FT                   /evidence="ECO:0000269|PubMed:11877398"
FT   CARBOHYD        791
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        876
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   MUTAGEN         311
FT                   /note="S->A: No effect on phosphorylation by PKC."
FT                   /evidence="ECO:0000269|PubMed:11877398"
FT   MUTAGEN         554
FT                   /note="S->A: Reduces phosphorylation by PKC and PKC-
FT                   mediated inhibition."
FT                   /evidence="ECO:0000269|PubMed:11877398"
FT   MUTAGEN         660
FT                   /note="S->A: Abolishes phosphorylation by PKA and PKA-
FT                   mediated down-regulation of enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:9391159"
FT   MUTAGEN         660
FT                   /note="S->A: Reduces phosphorylation by PKC and PKC-
FT                   mediated inhibition."
FT                   /evidence="ECO:0000269|PubMed:11877398"
FT   MUTAGEN         917
FT                   /note="T->A: Reduces phosphorylation by PKC, abolishes PKC-
FT                   mediated inhibition."
FT                   /evidence="ECO:0000269|PubMed:11877398"
FT   CONFLICT        80
FT                   /note="K -> E (in Ref. 2; AAA40678)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        130
FT                   /note="R -> P (in Ref. 2; AAA40678)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        538
FT                   /note="G -> A (in Ref. 2; AAA40678)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        790
FT                   /note="I -> L (in Ref. 2; AAA40678)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1166 AA;  130506 MW;  5042C650546E4E79 CRC64;
     MSWFSGLLVP KVDERKTAWG ERNGQKRPRQ ATRARGFCAP RYMSCLKNVE PPSPTPAART
     RCPWQDEAFI RRAGPGRGVK LGLRSVALGF DDTEVTTPMG TAEVAPDTSP RSGPSCWHRL
     AQVFQSKQFR SAKLERLYQR YFFQMNQSSL TLLMAVLVLL MAVLLTFHAA PALPQPAYVA
     LLTCASVLFV VLMVVCNRHS FRQDSMWVVS YVVLGILAAV QVGGALAANP RSPSAGLWCP
     VFFVYITYTL LPIRMRAAVL SGLGLSTLHL ILAWHLNNGD PFLWKQLGAN VVLFLCTNAI
     GVCTHYPAEV SQRQAFQETR GYIQARLHLQ HENRQQERLL LSVLPQHVAM EMKEDINTKK
     EDMMFHKIYI QKHDNVSILF ADIEGFTSLA SQCTAQELVM TLNELFARFD KLAAENHCLR
     IKILGDCYYC VSGLPEARAD HAHCCVEMGV DMIEAISLVR EVTGVNVNMR VGIHSGRVHC
     GVLGLRKWQF DVWSNDVTLA NHMEAGGRAG RIHITRATLQ YLNGDYEVEP GRGGERNGYL
     KEQCIETFLI LGASQKRKEE KAMLVKLQRT RANSMEGLMP RWVPDRAFSR TKDSKAFRQM
     GIDDSSKENR GAQDALNPED EVDEFLGRAI DARSIDQLRK DHVRRFLLTF QREDLEKKYS
     RKVDPRFGAY VACALLVFCF ICFIQFLVFP HSALILGIYA GIFLLLLVTV LICAVCSCGS
     FFPNALQRLS RSIVRSRVHS TAVGVFSVLL VFISAIANMF TCSHTPLRTC AARMLNLTPS
     DVTACHLRQI NYSLGLEAPL CEGTAPTCSF PEYFVGSVLL SLLASSVFLH ISSIGKLVMT
     FVLGFIYLLL LLLGPPATIF DNYDLLLSVH GLASSNETFD GLDCPAVGRV ALKYMTPVIL
     LVFALALYLH AQQVESTARL DFLWKLQATG EKEEMEELQA YNRRLLHNIL PKDVAAHFLA
     RERRNDELYY QSCECVAVMF ASIANFSEFY VELEANNEGV ECLRLLNEII ADFDEIISEE
     RFRQLEKIKT IGSTYMAASG LNASTYDQVG RSHITALADY AMRLMEQMKH INEHSFNNFQ
     MKIGLNMGPV VAGVIGARKP QYDIWGNTVN VSSRMDSTGV PDRIQVTTDL YQVLAAKGYQ
     LECRGVVKVK GKGEMTTYFL NGGPSS
//
